BioNTech

New Capabilities

Co-developer of trastuzumab pamirtecan; discussing a potential regulatory filing with DualityBio

BioNTech and DualityBio's Phase 3 breast cancer trial met its main goal, but the result is muted. Trastuzumab pamirtecan delayed tumor growth longer than chemotherapy in 541 patients with hormone receptor-positive, HER2-low metastatic breast cancer, a gain the companies call "statistically significant, yet modest."

Updated Yesterday

New Capabilities

Developer of BNT113, the mRNA cancer immunotherapy under evaluation

BioNTech's mRNA cancer drug BNT113, added to Merck's Keytruda, did not hold off HPV16-positive head and neck cancer longer than Keytruda alone. The miss, reported Oct. 13, was the first of the Phase 2/3 AHEAD-MERIT trial's two main goals, and US-listed BioNTech shares fell about 7% that day.

Updated Oct 30

New Capabilities

As of July 2026: BNT111 development exited in late-stage melanoma; Phase 2/3 trials continuing for BNT113 (head and neck cancer) and BNT116 (lung cancer)

Metastatic breast cancer typically kills most patients within five years. A small group of women vaccinated in a Duke University clinical trial two decades ago have defied that prognosis entirely; all remain alive today. Researchers found these survivors still carry specialized immune cells that recognize their cancer, offering a model for why some therapeutic vaccines produce lasting results.

Updated Jul 9